메뉴 건너뛰기




Volumn 8, Issue 1, 2012, Pages 18-21

A novel improved therapy strategy for diabetic nephropathy: Targeting AGEs

Author keywords

Advanced glycation end products; Core shell nanoparticles; Diabetic nephropathy; Dual target; Receptor for advanced glycation end products

Indexed keywords

ADVANCED GLYCATION END PRODUCT; ADVANCED GLYCATION END PRODUCT INHIBITOR; ADVANCED GLYCATION END PRODUCT RECEPTOR; ADVANCED GLYCATION END PRODUCT RECEPTOR INHIBITOR; ALDOSE REDUCTASE INHIBITOR; AMINOGUANIDINE; CARBOHYDRATE DERIVATIVE; IRBESARTAN; NANOCARRIER; NANOPARTICLE; NIFEDIPINE; OLMESARTAN; UNCLASSIFIED DRUG;

EID: 84862844811     PISSN: 15476278     EISSN: 15558592     Source Type: Journal    
DOI: 10.4161/org.19332     Document Type: Review
Times cited : (30)

References (38)
  • 1
    • 34548397224 scopus 로고    scopus 로고
    • Molecular mechanisms of diabetic nephropathy and its therapeutic intervention
    • PMID:17691932
    • Yamagishi S, Fukami K, Ueda S, Okuda S. Molecular mechanisms of diabetic nephropathy and its therapeutic intervention. Curr Drug Targets 2007; 8: 952-9; PMID:17691932; http://dx.doi.org/10.2174/ 138945007781386884
    • (2007) Curr Drug Targets , vol.8 , pp. 952-959
    • Yamagishi, S.1    Fukami, K.2    Ueda, S.3    Okuda, S.4
  • 2
    • 65649098711 scopus 로고    scopus 로고
    • Therapeutic strategies in the treatment of diabetic nephropathy-a translational medicine approach
    • PMID:19275608
    • Shah IM, Mackay SP, McKay GA. Therapeutic strategies in the treatment of diabetic nephropathy-a translational medicine approach. Curr Med Chem 2009; 16:997-1016; PMID:19275608; http://dx.doi. org/10.2174/092986709787581897
    • (2009) Curr Med Chem , vol.16 , pp. 997-1016
    • Shah, I.M.1    Mackay, S.P.2    McKay, G.A.3
  • 3
    • 55249114365 scopus 로고    scopus 로고
    • Diabetic nephropathy: Important pathophysiologic mechanisms
    • PMID:18994672
    • Soldatos G, Cooper ME. Diabetic nephropathy: important pathophysiologic mechanisms. Diabetes Res Clin Pract 2008; 82(Suppl 1):S75-9; PMID:18994672; http://dx.doi.org/10.1016/j.diabres.2008.09.042
    • (2008) Diabetes Res Clin Pract , vol.82 , Issue.SUPPL. 1
    • Soldatos, G.1    Cooper, M.E.2
  • 4
    • 33646429192 scopus 로고    scopus 로고
    • Relationship between the expression of advanced glycation end-products (AGE) and the receptor for AGE (RAGE) mRNA in diabetic nephropathy
    • PMID: 16679697
    • Suzuki D, Toyoda M, Yamamoto N, Miyauchi M, Katoh M, Kimura M, et al. Relationship between the expression of advanced glycation end-products (AGE) and the receptor for AGE (RAGE) mRNA in diabetic nephropathy. Intern Med 2006; 45:435-41; PMID: 16679697; http://dx.doi.org/10.2169/internalmedicine. 45.1557
    • (2006) Intern Med , vol.45 , pp. 435-441
    • Suzuki, D.1    Toyoda, M.2    Yamamoto, N.3    Miyauchi, M.4    Katoh, M.5    Kimura, M.6
  • 5
    • 44449132702 scopus 로고    scopus 로고
    • Role of AGEs in diabetic nephropathy
    • PMID:18473844
    • Fukami K, Yamagishi S, Ueda S, Okuda S. Role of AGEs in diabetic nephropathy. Curr Pharm Des 2008; 14:946-52; PMID:18473844; http://dx.doi.org/ 10. 2174/138161208784139710
    • (2008) Curr Pharm Des , vol.14 , pp. 946-952
    • Fukami, K.1    Yamagishi, S.2    Ueda, S.3    Okuda, S.4
  • 6
    • 0035135246 scopus 로고    scopus 로고
    • Advanced glycation end-products: A review
    • PMID:11270668
    • Singh R, Barden A, Mori T, Beilin L. Advanced glycation end-products: a review. Diabetologia 2001; 44:129-46; PMID:11270668; http://dx.doi.org/10. 1007/s001250051591
    • (2001) Diabetologia , vol.44 , pp. 129-146
    • Singh, R.1    Barden, A.2    Mori, T.3    Beilin, L.4
  • 7
    • 44449132702 scopus 로고    scopus 로고
    • Role of AGEs in diabetic nephropathy
    • PMID:18473844
    • Fukami K, Yamagishi S, Ueda S, Okuda S. Role of AGEs in diabetic nephropathy. Curr Pharm Des 2008; 14:946-52; PMID:18473844; http://dx.doi.org/ 10. 2174/138161208784139710
    • (2008) Curr Pharm Des , vol.14 , pp. 946-952
    • Fukami, K.1    Yamagishi, S.2    Ueda, S.3    Okuda, S.4
  • 8
    • 0037406905 scopus 로고    scopus 로고
    • Glucose, glycation, and RAGE: Implications for amplification of cellular dysfunction in diabetic nephropathy
    • PMID:12707408
    • Wendt T, Tanji N, Guo J, Hudson BI, Bierhaus A, Ramasamy R, et al. Glucose, glycation, and RAGE: implications for amplification of cellular dysfunction in diabetic nephropathy. J Am Soc Nephrol 2003; 14:1383-95; PMID:12707408; http://dx.doi.org/10. 1097/01.ASN.0000065100.17349.CA
    • (2003) J Am Soc Nephrol , vol.14 , pp. 1383-1395
    • Wendt, T.1    Tanji, N.2    Guo, J.3    Hudson, B.I.4    Bierhaus, A.5    Ramasamy, R.6
  • 9
    • 0035153678 scopus 로고    scopus 로고
    • Advanced glycation end products, their receptors and diabetic angiopathy
    • PMID:11694852
    • Wautier JL, Guillausseau PJ. Advanced glycation end products, their receptors and diabetic angiopathy. Diabetes Metab 2001; 27:535-42; PMID:11694852
    • (2001) Diabetes Metab , vol.27 , pp. 535-542
    • Wautier, J.L.1    Guillausseau, P.J.2
  • 10
    • 27744453362 scopus 로고    scopus 로고
    • Understanding RAGE, the receptor for advanced glycation end products
    • (Berl) PMID:16133426
    • Bierhaus A, Humpert PM, Morcos M, Wendt T, Chavakis T, Arnold B, et al. Understanding RAGE, the receptor for advanced glycation end products. J Mol Med (Berl) 2005; 83:876-86; PMID:16133426; http:// dx.doi.org/10.1007/s00109-005- 0688-7
    • (2005) J Mol Med , vol.83 , pp. 876-886
    • Bierhaus, A.1    Humpert, P.M.2    Morcos, M.3    Wendt, T.4    Chavakis, T.5    Arnold, B.6
  • 11
    • 0028068046 scopus 로고
    • Cellular receptors for advanced glycation end products. Implications for induction of oxidant stress and cellular dysfunction in the pathogenesis of vascular lesions
    • PMID: 7918300
    • Schmidt AM, Hori O, Brett J, Yan SD, Wautier JL, Stern D. Cellular receptors for advanced glycation end products. Implications for induction of oxidant stress and cellular dysfunction in the pathogenesis of vascular lesions. Arterioscler Thromb 1994; 14:1521-8; PMID: 7918300; http://dx.doi.org/10.1161/ 01.ATV.14.10. 1521
    • (1994) Arterioscler Thromb , vol.14 , pp. 1521-1528
    • Schmidt, A.M.1    Hori, O.2    Brett, J.3    Yan, S.D.4    Wautier, J.L.5    Stern, D.6
  • 12
    • 3042637228 scopus 로고    scopus 로고
    • Role of advanced glycation end products (AGEs) and their receptor (RAGE) in the pathogenesis of diabetic microangiopathy
    • PMID:15224502
    • Yamagishi S, Takeuchi M, Inagaki Y, Nakamura K, Imaizumi T. Role of advanced glycation end products (AGEs) and their receptor (RAGE) in the pathogenesis of diabetic microangiopathy. Int J Clin Pharmacol Res 2003; 23:129-34; PMID:15224502
    • (2003) Int J Clin Pharmacol Res , vol.23 , pp. 129-134
    • Yamagishi, S.1    Takeuchi, M.2    Inagaki, Y.3    Nakamura, K.4    Imaizumi, T.5
  • 13
    • 63049117088 scopus 로고    scopus 로고
    • Interactions between advanced glycation end-products (AGE) and their receptors in the development and progression of diabetic nephropathy-are these receptors valid therapeutic targets
    • PMID:19149535
    • Sourris KC, Forbes JM. Interactions between advanced glycation end-products (AGE) and their receptors in the development and progression of diabetic nephropathy-are these receptors valid therapeutic targets. Curr Drug Targets 2009; 10:42-50; PMID:19149535; http://dx. doi.org/10.2174/ 138945009787122905
    • (2009) Curr Drug Targets , vol.10 , pp. 42-50
    • Sourris, K.C.1    Forbes, J.M.2
  • 14
    • 0035856980 scopus 로고    scopus 로고
    • Biochemistry and molecular cell biology of diabetic complications
    • PMID:11742414
    • Brownlee M. Biochemistry and molecular cell biology of diabetic complications. Nature 2001; 414:813-20; PMID:11742414; http://dx.doi.org/10. 1038/414813a
    • (2001) Nature , vol.414 , pp. 813-820
    • Brownlee, M.1
  • 15
    • 17144391517 scopus 로고    scopus 로고
    • Agents in development for the treatment of diabetic nephropathy
    • PMID: 15833059
    • Fukami K, Cooper ME, Forbes JM. Agents in development for the treatment of diabetic nephropathy. Expert Opin Investig Drugs 2005; 14:279-94; PMID: 15833059; http://dx.doi.org/10.1517/13543784.14.3. 279
    • (2005) Expert Opin Investig Drugs , vol.14 , pp. 279-294
    • Fukami, K.1    Cooper, M.E.2    Forbes, J.M.3
  • 16
    • 76649145110 scopus 로고    scopus 로고
    • Advanced glycation end-products: Implications for diabetic and nondiabetic nephropathies
    • PMID:19932633
    • Daroux M, Prévost G, Maillard-Lefebvre H, Gaxatte C, D'Agati VD, Schmidt AM, et al. Advanced glycation end-products: implications for diabetic and nondiabetic nephropathies. Diabetes Metab 2010; 36:1-10; PMID:19932633; http://dx.doi.org/10.1016/j.diabet. 2009.06.005
    • (2010) Diabetes Metab , vol.36 , pp. 1-10
    • Daroux, M.1    Prévost, G.2    Maillard-Lefebvre, H.3    Gaxatte, C.4    D'Agati, V.D.5    Schmidt, A.M.6
  • 17
    • 0037374652 scopus 로고    scopus 로고
    • New therapies for advanced glycation end product nephrotoxicity: Current challenges
    • PMID:12612951
    • Williams ME. New therapies for advanced glycation end product nephrotoxicity: current challenges. Am J Kidney Dis 2003; 41(Suppl 1):S42-7; PMID:12612951; http://dx.doi.org/10.1053/ajkd.2003.50083
    • (2003) Am J Kidney Dis , vol.41 , Issue.SUPPL. 1
    • Williams, M.E.1
  • 18
    • 72749121317 scopus 로고    scopus 로고
    • Irbesartan inhibits advanced glycation end product (AGE)-induced proximal tubular cell injury in vitro by suppressing receptor for AGEs (RAGE) expression
    • PMID: 19635564
    • Matsui T, Yamagishi S, Takeuchi M, Ueda S, Fukami K, Okuda S. Irbesartan inhibits advanced glycation end product (AGE)-induced proximal tubular cell injury in vitro by suppressing receptor for AGEs (RAGE) expression. Pharmacol Res 2010; 61:34-9; PMID: 19635564; http://dx.doi.org/10.1016/j.phrs.2009.07. 004
    • (2010) Pharmacol Res , vol.61 , pp. 34-39
    • Matsui, T.1    Yamagishi, S.2    Takeuchi, M.3    Ueda, S.4    Fukami, K.5    Okuda, S.6
  • 19
    • 73949118948 scopus 로고    scopus 로고
    • Glucagon-like peptide-1 (GLP-1) inhibits advanced glycation end product (AGE)-induced up-regulation of VCAM-1 mRNA levels in endothelial cells by suppressing AGE receptor (RAGE) expression
    • PMID: 20026306
    • Ishibashi Y, Matsui T, Takeuchi M, Yamagishi S. Glucagon-like peptide-1 (GLP-1) inhibits advanced glycation end product (AGE)-induced up-regulation of VCAM-1 mRNA levels in endothelial cells by suppressing AGE receptor (RAGE) expression. Biochem Biophys Res Commun 2010; 391:1405-8; PMID: 20026306; http://dx.doi.org/10.1016/j.bbrc.2009.12. 075
    • (2010) Biochem Biophys Res Commun , vol.391 , pp. 1405-1408
    • Ishibashi, Y.1    Matsui, T.2    Takeuchi, M.3    Yamagishi, S.4
  • 20
    • 67349131842 scopus 로고    scopus 로고
    • Nifedipine, a calcium channel blocker, inhibits advanced glycation end product (AGE)-elicited mesangial cell damage by suppressing AGE receptor (RAGE) expression via peroxisome proliferator-activated receptor-gamma activation
    • PMID:19460355
    • Matsui T, Yamagishi S, Takeuchi M, Ueda S, Fukami K, Okuda S. Nifedipine, a calcium channel blocker, inhibits advanced glycation end product (AGE)-elicited mesangial cell damage by suppressing AGE receptor (RAGE) expression via peroxisome proliferator-activated receptor-gamma activation. Biochem Biophys Res Commun 2009; 385:269-72; PMID:19460355; http://dx.doi.org/ 10.1016/j.bbrc.2009.05.061
    • (2009) Biochem Biophys Res Commun , vol.385 , pp. 269-272
    • Matsui, T.1    Yamagishi, S.2    Takeuchi, M.3    Ueda, S.4    Fukami, K.5    Okuda, S.6
  • 21
    • 33947386181 scopus 로고    scopus 로고
    • Soluble RAGE but not endogenous secretory RAGE is associated with albuminuria in patients with type 2 diabetes
    • PMID:17343760
    • Humpert PM, Djuric Z, Kopf S, Rudofsky G, Morcos M, Nawroth PP, et al. Soluble RAGE but not endogenous secretory RAGE is associated with albuminuria in patients with type 2 diabetes. Cardiovasc Diabetol 2007; 6:9; PMID:17343760; http://dx.doi. org/10.1186/1475-2840-6-9
    • (2007) Cardiovasc Diabetol , vol.6 , pp. 9
    • Humpert, P.M.1    Djuric, Z.2    Kopf, S.3    Rudofsky, G.4    Morcos, M.5    Nawroth, P.P.6
  • 22
    • 33947408459 scopus 로고    scopus 로고
    • Association between serum levels of soluble receptor for advanced glycation end products and circulating advanced glycation end products in type 2 diabetes
    • PMID:16969649
    • Tan KC, Shiu SW, Chow WS, Leng L, Bucala R, Betteridge DJ. Association between serum levels of soluble receptor for advanced glycation end products and circulating advanced glycation end products in type 2 diabetes. Diabetologia 2006; 49:2756-62; PMID:16969649; http://dx.doi.org/10.1007/s00125- 006-0394-1
    • (2006) Diabetologia , vol.49 , pp. 2756-2762
    • Tan, K.C.1    Shiu, S.W.2    Chow, W.S.3    Leng, L.4    Bucala, R.5    Betteridge, D.J.6
  • 23
    • 9244247342 scopus 로고    scopus 로고
    • Synthesis and in vitro testing of J591 antibody-dendrimer conjugates for targeted prostate cancer therapy
    • PMID:15546182
    • Patri AK, Myc A, Beals J, Thomas TP, Bander NH, Baker JR, Jr. Synthesis and in vitro testing of J591 antibody-dendrimer conjugates for targeted prostate cancer therapy. Bioconjug Chem 2004; 15:1174-81; PMID:15546182; http://dx.doi.org/10.1021/bc0499127
    • (2004) Bioconjug Chem , vol.15 , pp. 1174-1181
    • Patri, A.K.1    Myc, A.2    Beals, J.3    Thomas, T.P.4    Bander, N.H.5    Baker Jr., J.R.6
  • 24
    • 17644395605 scopus 로고    scopus 로고
    • Glycodendrimeric nanoparticulate carriers of primaquine phosphate for liver targeting
    • PMID:15848007
    • Bhadra D, Yadav AK, Bhadra S, Jain NK. Glycodendrimeric nanoparticulate carriers of primaquine phosphate for liver targeting. Int J Pharm 2005; 295:221-33; PMID:15848007; http://dx.doi.org/10.1016/j.ijpharm. 2005.01.026
    • (2005) Int J Pharm , vol.295 , pp. 221-233
    • Bhadra, D.1    Yadav, A.K.2    Bhadra, S.3    Jain, N.K.4
  • 25
    • 60149100143 scopus 로고    scopus 로고
    • Targeting cancer cells with biotin-dendrimer conjugates
    • PMID: 18550227
    • Yang WJ, Cheng YY, Xu TW, Wang XY, Wen LP. Targeting cancer cells with biotin-dendrimer conjugates. Eur J Med Chem 2009; 44:862-8; PMID: 18550227; http://dx.doi.org/10.1016/j.ejmech.2008. 04.021
    • (2009) Eur J Med Chem , vol.44 , pp. 862-868
    • Yang, W.J.1    Cheng, Y.Y.2    Xu, T.W.3    Wang, X.Y.4    Wen, L.P.5
  • 27
    • 67349117682 scopus 로고    scopus 로고
    • Recent advances in pharmacotherapy for diabetic nephropathy: Current perspectives and future directions
    • PMID:19427582
    • Balakumar P, Arora MK, Ganti SS, Reddy J, Singh M. Recent advances in pharmacotherapy for diabetic nephropathy: current perspectives and future directions. Pharmacol Res 2009; 60:24-32; PMID:19427582; http://dx.doi.org/10. 1016/j.phrs.2009.02.002
    • (2009) Pharmacol Res , vol.60 , pp. 24-32
    • Balakumar, P.1    Arora, M.K.2    Ganti, S.S.3    Reddy, J.4    Singh, M.5
  • 28
    • 35348922424 scopus 로고    scopus 로고
    • Role of the AGE crosslink breaker, alagebrium, as a renoprotective agent in diabetes
    • PMID:17653212
    • Coughlan MT, Forbes JM, Cooper ME. Role of the AGE crosslink breaker, alagebrium, as a renoprotective agent in diabetes. Kidney Int Suppl 2007; 106:S54- 60; PMID:17653212; http://dx.doi.org/10.1038/sj.ki. 5002387
    • (2007) Kidney Int Suppl , vol.106
    • Coughlan, M.T.1    Forbes, J.M.2    Cooper, M.E.3
  • 29
    • 35548975242 scopus 로고    scopus 로고
    • Effects of pyridoxamine in combined phase 2 studies of patients with type 1 and type 2 diabetes and overt nephropathy
    • PMID:17823506
    • Williams ME, Bolton WK, Khalifah RG, Degenhardt TP, Schotzinger RJ, McGill JB. Effects of pyridoxamine in combined phase 2 studies of patients with type 1 and type 2 diabetes and overt nephropathy. Am J Nephrol 2007; 27:605-14; PMID:17823506; http://dx.doi.org/ 10.1159/000108104
    • (2007) Am J Nephrol , vol.27 , pp. 605-614
    • Williams, M.E.1    Bolton, W.K.2    Khalifah, R.G.3    Degenhardt, T.P.4    Schotzinger, R.J.5    McGill, J.B.6
  • 30
    • 23744516038 scopus 로고    scopus 로고
    • Post-Amadori AGE inhibition as a therapeutic target for diabetic complications: A rational approach to second-generation Amadorin design
    • PMID:16037307
    • Khalifah RG, Chen Y, Wassenberg JJ. Post-Amadori AGE inhibition as a therapeutic target for diabetic complications: a rational approach to second-generation Amadorin design. Ann N Y Acad Sci 2005; 1043:793- 806; PMID:16037307; http://dx.doi.org/10.1196/ annals.1333.092
    • (2005) Ann N Y Acad Sci , vol.1043 , pp. 793-806
    • Khalifah, R.G.1    Chen, Y.2    Wassenberg, J.J.3
  • 31
    • 72749121317 scopus 로고    scopus 로고
    • Irbesartan inhibits advanced glycation end product (AGE)-induced proximal tubular cell injury in vitro by suppressing receptor for AGEs (RAGE) expression
    • PMID: 19635564
    • Matsui T, Yamagishi S, Takeuchi M, Ueda S, Fukami K, Okuda S. Irbesartan inhibits advanced glycation end product (AGE)-induced proximal tubular cell injury in vitro by suppressing receptor for AGEs (RAGE) expression. Pharmacol Res 2010; 61:34-9; PMID: 19635564; http://dx.doi.org/10.1016/j.phrs.2009.07. 004
    • (2010) Pharmacol Res , vol.61 , pp. 34-39
    • Matsui, T.1    Yamagishi, S.2    Takeuchi, M.3    Ueda, S.4    Fukami, K.5    Okuda, S.6
  • 32
    • 37249065845 scopus 로고    scopus 로고
    • Olmesartan blocks advanced glycation end products (AGEs)-induced angiogenesis in vitro by suppressing receptor for AGEs (RAGE) expression
    • PMID:17560613
    • Yamagishi S, Matsui T, Nakamura K, Inoue H, Takeuchi M, Ueda S, et al. Olmesartan blocks advanced glycation end products (AGEs)-induced angiogenesis in vitro by suppressing receptor for AGEs (RAGE) expression. Microvasc Res 2008; 75: 130-4; PMID:17560613; http://dx.doi.org/10.1016/j. mvr.2007.05.001
    • (2008) Microvasc Res , vol.75 , pp. 130-134
    • Yamagishi, S.1    Matsui, T.2    Nakamura, K.3    Inoue, H.4    Takeuchi, M.5    Ueda, S.6
  • 33
    • 0032685198 scopus 로고    scopus 로고
    • Magnetic core-shell particles: Preparation of magnetite multilayers on polymer latex microspheres
    • Deerfield Beach Fla
    • Caruso F, Susha AS, Giersig M, Mohwald H. Magnetic core-shell particles: preparation of magnetite multilayers on polymer latex microspheres. Adv Mater (Deerfield Beach Fla) 1999; 11:950-3; http://dx.doi. org/10.1002/(SICI)1521- 4095(199908)11:11,950:: AID-ADMA950.3.0.CO;2-T
    • (1999) Adv Mater , vol.11 , pp. 950-953
    • Caruso, F.1    Susha, A.S.2    Giersig, M.3    Mohwald, H.4
  • 34
    • 0035908572 scopus 로고    scopus 로고
    • Multilayer assemblies of silicaencapsulated gold nanoparticles on decomposable colloid templates
    • Deerfield Beach Fla
    • Caruso F, Spasova M. Multilayer assemblies of silicaencapsulated gold nanoparticles on decomposable colloid templates. Adv Mater (Deerfield Beach Fla) 2001; 13:1090-4; http://dx.doi.org/10.1002/1521- 4095(200107)13:14,1090::AID- ADMA1090.3.0. CO;2-H
    • (2001) Adv Mater , vol.13 , pp. 1090-1094
    • Caruso, F.1    Spasova, M.2
  • 35
    • 0037419891 scopus 로고    scopus 로고
    • A method for making inorganic and hybrid (organic/inorganic) fibers and vesicles with diameters in the submicrometer and micrometer range via sol-gel chemistry and electrically forced liquid jets
    • PMID:12553802
    • Larsen G, Velarde-Ortiz R, Minchow K, Barrero A, Loscertales IG. A method for making inorganic and hybrid (organic/inorganic) fibers and vesicles with diameters in the submicrometer and micrometer range via sol-gel chemistry and electrically forced liquid jets. J Am Chem Soc 2003; 125:1154-5; PMID:12553802; http://dx.doi.org/10.1021/ja028983i
    • (2003) J Am Chem Soc , vol.125 , pp. 1154-1155
    • Larsen, G.1    Velarde-Ortiz, R.2    Minchow, K.3    Barrero, A.4    Loscertales, I.G.5
  • 36
    • 0035914220 scopus 로고    scopus 로고
    • Fabrication, characterization and in vitro release of paclitaxel (Taxol) loaded poly (lactic-coglycolic acid) microspheres prepared by spray drying technique with lipid/cholesterol emulsifiers
    • PMID:11578739
    • Mu L, Feng SS. Fabrication, characterization and in vitro release of paclitaxel (Taxol) loaded poly (lactic-coglycolic acid) microspheres prepared by spray drying technique with lipid/cholesterol emulsifiers. J Control Release 2001; 76:239-54; PMID:11578739; http://dx. doi.org/10.1016/S0168-3659(01)00440-0
    • (2001) J Control Release , vol.76 , pp. 239-254
    • Mu, L.1    Feng, S.S.2
  • 38
    • 34249894977 scopus 로고    scopus 로고
    • Targeting cancer cells using PLGA nanoparticles surface modified with monoclonal antibody
    • PMID:17509712
    • Kocbek P, Obermajer N, Cegnar M, Kos J, Kristl J. Targeting cancer cells using PLGA nanoparticles surface modified with monoclonal antibody. J Control Release 2007; 120:18-26; PMID:17509712; http://dx.doi.org/ 10.1016/j.jconrel. 2007.03.012
    • (2007) J Control Release , vol.120 , pp. 18-26
    • Kocbek, P.1    Obermajer, N.2    Cegnar, M.3    Kos, J.4    Kristl, J.5


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.